New Antibody-Drug Therapy Cuts Death Risk in Advanced Endometrial Cancer
A phase 3 trial found sacituzumab tirumotecan significantly lowered disease progression and mortality in women with recurrent endometrial cancer after prior PD-1 therapy.
An international phase-3 study led by NYU Langone Health’s Perlmutter Cancer Center evaluated sacituzumab tirumotecan, an antibody-drug conjugate that binds the Trop-2 protein on endometrial tumor cells, against physician-chosen chemotherapy in women with advanced or recurrent disease who had already received a PD-1 inhibitor. The investigational therapy cut the risk of cancer progression by 41% and reduced overall mortality by 32% relative to chemotherapy, while 35% of patients achieved tumor shrinkage—over twice the rate seen with standard treatment.
Researchers noted common side effects such as low blood counts, mouth inflammation and dry or itchy eyes, but reported they were manageable. The findings echo Merck’s TroFuse-005 trial, which also demonstrated statistically significant improvements with sac-TMT. Both studies suggest the drug could become a new standard for recurrent endometrial cancer and may be explored in other Trop-2-rich tumors. Consequently, the investigators recommend revising clinical guidelines to incorporate sacituzumab tirumotecan.
Why it matters
It offers a more effective, targeted option for a cancer that kills tens of thousands of women each year.
In this story
